Overview

A Safety Study of Mebendazole in Children 2 to 10 Years of Age

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the safety and tolerability of mebendazole 500-mg chewable tablet formulation in a pediatric population. Mebendazole is a drug used for the treatment of soil-transmitted parasitic helminth (STH) (ie, parasitic worm) infections such as pinworm, whipworm, common roundworm, common hookworm, and American hookworm.
Phase:
Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatments:
DMP 777
Mebendazole
Piperazine
Piperazine citrate
Criteria
Inclusion Criteria:

- Be an otherwise healthy child based on medical history, physical examination, vital
signs, and concomitant medications and live in a high-prevalence area where parasite
infection is endemic (ie, Prevalent in or peculiar to a particular locality, region,
or people)

- Have teeth and be able to chew the mebendazole chewable tablet

- Girls must be premenarchal

- Parent(s)/guardians of study participants (or their legally-accepted representatives)
must have signed an informed consent document indicating that they understand the
purpose of and procedures required for the study and are willing to have their child
participate in the study

Exclusion Criteria:

- Have a history of clinically significant liver or renal insufficiency

- cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic
(eg, anemia), rheumatologic, psychiatric, or metabolic disturbances that, in the
opinion of the investigator, renders the candidate not suitable for mebendazole
treatment

- Have a suspected massive intestinal parasitic infection, based on history and physical
findings, as determined by the principal investigator

- Have any condition that, in the opinion of the investigator, would compromise the
well-being of the study participant or the study or prevent the study participant from
meeting or performing study requirements